Beijing Warns Three Major Insurance Companies Over Foreign Investments

China’s government took further steps to clamp down on the nation’s insurance sector by issuing warning on Saturday to three major insurers related to their overseas investments, just one day after the government seized temporary control of Anbang Insurance Group. China Insurance Regulatory Commission (CIRC) issued warning notices to Ping An Insurance (Group) Co. of China, New China Life Insurance and China Re Asset Management Co., saying they had violated official rules regarding overseas investments. The notices did not, however, provide …

China’s Insurance Regulator To Take Over Troubled Anbang, Chairman Wu Xiaohui Prosecuted For Alleged Economic Crime

China’s insurance regulator has decided to takeover Anbang Insurance Group, a once high-flying insurance company headed by Wu Xiaohui, ex-husband to the granddaughter of former Chinese paramount leader Deng Xiaoping. In a statement posted on the China Insurance Regulatory Committee (CIRC), Wu Xiaohui, Anbang’s ex-chairman, has been prosecuted for alleged economic crimes by a court in Shanghai.

China’s Direct Investment In US Drops 35% With Value Of New Acquisitions Reduced By 90% In 2017 Due To Regulatory Hurdles

China’s direct investment in the United States dropped by 35% in 2017 to US$29 billion in completed deals, and the value of newly announced Chinese acquisitions in the U.S. dropped by 90% compared to 2016, due to regulatory hurdles from both countries, according to a report by Rhodium Group, a research consultancy based in New York. 

RYB’s Child Abuse Scandal Reflects Poor Diligence By Top Investors Including Hillhouse, Greenwoods

The child abuse scandal at RYB Education Inc. (NYSE:RYB) reduced its stock price by nearly 40% last week, just three months after the company’s New York Stock Exchange IPO. The collapse has cost the company’s top ten institutional investors, including China’s largest private equity fund Hillhouse Capital and well-known investment management firm Greenwoods Asset Management, a combined US$52 million on paper. But the losses might have been avoided if investors had taken into account some inherent weaknesses in RYB’s business …

Bloomberg Launches New RMB Bond Suite For Global Investors

RMB Bond Suite features the industry’s most advanced fixed income investment tools for China’s interbank bond market

BEIJING and HONG KONG, May 18, 2017 /PRNewswire/ — Bloomberg today announced the launch of its new RMB Bond Suite, the industry’s most advanced fixed income investment tools for China’s vast bond market, now the world’s third-largest debt market valued at over $9 trillion. Bloomberg’s RMB Bond Suite covers rate and credit, and includes critical fixed income data, real time curves and economic indicators, combined with Bloomberg’s powerful analytics.

generated by system

"As China’s burgeoning interbank bond market continues to open up to foreign participation, global investors need an increasingly sophisticated set of tools to help them gain deeper insight and an edge into its market opportunities," said Ee Chuan Ng, Bloomberg’s head of China. "By bringing our deep fixed income expertise and heritage to China, we believe the RMB Bond Suite will enhance market transparency, and redefine the workflow for both onshore and offshore investors."

Over the last year, China has taken steps to open up its bond market while Chinese financial regulators focus on deleveraging and risk mitigation in the financial sector.  The deleveraging campaign has driven volatility in China’s bond market, caused yields to rise and widened credit spreads. The RMB Bond Suite gives investors a set of tools to perform deeper market analysis, thereby uncovering opportunities for trading and hedging.

The RMB Bond Suite features a China brokers page, or MOSB CN <GO>, with real-time trade data from five money brokers1 providing the most liquidity. It also includes bond issuance data, company fundamental information, market-recognized league tables, market share analysis, real-time benchmark yield curves, news headlines, PBOC’s open market operations calculator, bond futures pricing tools and comprehensive credit analytics.

Powered by Bloomberg’s best-in-class analytics, portfolio managers can now view historical yield movement of bonds, discover the most liquid bond of each tenor or across the whole market, link this data into their trading workflow and build customized curves of selected bonds.

"Portfolio managers and traders now have an essential set of fixed income tools that can enable them to have a micro and a macro view of both the domestic fixed income market and overseas markets," said Dr. Luo Feng, General Manager of Financial Markets at China Zheshang Bank. "One of the best aspects of the Bloomberg’s RMB Bond Suite is how it supports the entire workflow – from fixed income price discovery, data, curves, analysis and news."

Based on a Bloomberg Singapore Buyside forum in March 2017, 59% of market participants say they are actively exploring to invest in the China bond market, and 29% say they are already investing in the market. The size of China’s local currency bonds currently equals a fifth of the Bloomberg Barclays Global Aggregate Index, a $45 trillion benchmark. According to China’s central bank data, by the end of 2016, over 400 foreign financial institutions have invested in China’s bond market, with total investment of about $120 billion (or 852 billion yuan).

"Over the medium to long term, China’s onshore debt will inevitably become a significant part of global fixed income portfolios," said Freddy Wong, Portfolio Manager at Fidelity International, who oversees the first private onshore bond fund launched by a global asset management firm in China. "There are huge investment opportunities in China’s onshore bond market. RMB assets (bonds and equities) are some of the most under-invested and under-allocated assets in the world. Undeniably, the RMB bond markets are the future of Asia’s bond markets and will play a dominant role in global financial markets in many years to come."

The launch of Bloomberg’s RMB Bond Suite is an extension of the company’s broader strategic focus on China’s fixed income market, following the recent inclusion of Chinese bonds into its global fixed income indices. In March 2017, Bloomberg was the first index provider to include China bonds in its global indices offering when it launched two new parallel fixed income indices that include RMB-denominated China bonds on top of the global indices under the Bloomberg Barclays Benchmark Fixed Income Index family.

About Bloomberg
Bloomberg, the global business and financial information and news leader, gives influential decision makers a critical edge by connecting them to a dynamic network of information, people and ideas. The company’s strength – delivering data, news and analytics through innovative technology, quickly and accurately – is at the core of the Bloomberg Professional service. Bloomberg’s enterprise solutions build on the company’s core strength: leveraging technology to allow customers to access, integrate, distribute and manage data and information across organizations more efficiently and effectively. For more information, visit or request a demo.

1 The five money brokers are Tullett Prebon Sitico (China) Co., China Credit BGC Money Broking Co., Cfets-ICAP International Money Broking Co., Ping An Tradition International Money Broking Co. and Citic Central Tanshi Money Brokering Co.


OpenStack Summit Boston Reveals New Users, New Growth With Remotely Managed Private Cloud, Edge Computing and Composable Infrastructure

Hong Kong, China, May 11, 2017 / – Speakers, demonstrations tout OpenStack’s power to drive innovation through composable open infrastructure that costs less, does more OpenStack Summit Boston — Thousands of participants from 60+ countries are attending OpenStack Summit Boston this week to discuss how to combine open source technologies including programmable infrastructure and container… Read More

Anbang Chief Wu Xiaohui Rumored To Be Detained For Illegal Loans

Chairman of Chinese insurance firm Anbang Insurance Group, Wu Xiaohui, who was the husband of the granddaughter of Deng Xiaoping, is rumored to have been detained by authorities in Beijing for illegal loans and potentially other allegations, according to reports circulating on Chinese social media networks since yesterday.

Eight Roads Ventures Leads Series C Round In Chinese Parenting Platform MAMA+

Eight Roads Ventures, formerly Fidelity Growth Partners, has led a series C round investment in Beijing-based parenting platform MAMA+. GSR Ventures, Lightspeed Venture Partners, Steamboat Ventures, the venture capital arm of The Walt Disney Company, and unnamed Chinese investment institutions also participated in the financing round, which is reportedly worth tens of million of U.S. dollars.

Eight Roads Ventures Supports Mothers in China with Series C Round in MAMA+

HONG KONG, April 6, 2017 /PRNewswire/ — MAMA+, which runs, a Chinese social commerce platform dedicated to helping mothers, has raised tens of millions of US dollars in a Series C round.  Eight Roads Ventures led the funding with participation by GSR Ventures, Core Capital, Steamboat Ventures, Lightspeed China Partners and GWC. Eight Roads is the proprietary investment arm of Fidelity International Limited, one of the largest investment management companies in the world. MAMA+ will use the funds to enhance user experience, strengthen its supply chain and expand its team. draws together a powerful online and offline community of mothers who share their experiences in ‘V-Friend Groups’, learn about parenthood in ‘Mama Classes’, attend events hosted by Key Opinion Leaders and purchase products for both themselves and their children. Two years after its launch in 2014, has an active user base of several millions across tier one and two cities in China. It is now steadily expanding into other tier two and three cities.

Parents in China are spending more on safe, higher quality and branded goods for their children. Mothers currently control 80% of household spend in China and the expected baby boom following the introduction of a two-child policy promises to further increase consumer spending on mother and child products. offers a highly-curated selection of products, based on trusted recommendations from key influencers and users and with strict quality control in place. To-date, over 8,000 books from 100+ publishers, and a wide-ranging selection of high quality, trusted products from 500+ global brands are available on the platform.

Fanghua Wu, Co-founder and CEO of MAMA+ commented, "A number of tier one USD funds approached us, and we eventually chose Eight Roads to lead this investment as we believe in their expertise in the consumer and ecommerce sector and our highly aligned visions in supporting mothers. We are confident Eight Roads’ strengths and resources will help us advance our strategy to further innovate our platform for the benefit of mothers and families in China."

Joe Chang, Partner of Eight Roads Ventures, said, "We are thrilled to be investors in an inspirational company like MAMA+ that is helping mothers to take better care of the most precious thing in their lives, their children. MAMA+ typifies the companies we aim to back in the consumer technology sector in China — companies who address important consumer needs and demonstrate their value through their explosive growth and the deep loyalty and overwhelmingly positive feedback of their customers."

He added, "Our investment in MAMA+ is reflective of our aims in investing in great companies in China who create deep value for their customers, and a continuation of our heritage in backing and helping build industry leaders like Alibaba, AsiaInfo, iSoftstone and WuXi PharmaTech."

About MAMA+

Beijing Bravetime Tech Co. Ltd. ("MAMA+") was established in October 2014 and received angel funding from Angel Plus in the same month. Since then, MAMA+ has received funding and support from a number of venture capitalists, namely GSR Ventures, Disney’s investment arm Steamboat Ventures, Lightspeed China Partners and LGT. In March 2017, MAMA+ closed its Series C funding led by Eight Roads Ventures with participation by top tier investors such as Core Capital and GWC.

MAMA+ runs a social commerce platform that focuses on parent-child reading and supports growth and learning in mothers. Two years on from its launch, has several millions of active users and becomes the largest Chinese mother community.

MAMA+’s vision is to help every mother become better. Its innovative community-based business model helps mothers improve household financial situations and realize individual values. In February 2017, MAMA+ signed the United Nation’s Women’s Empowerment Principles and became the 24th signatory company from China.

About Eight Roads Ventures

Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness. It has over 20 years of venture capital experience in China and has supported over 80 companies in the country’s healthcare, enterprise technology and consumer technology sectors. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses and together with its associated funds manages $4bn of capital across offices in China, Japan, UK, India and the US. @8roadsventures

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

SHANGHAI, Dec. 5, 2016 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion. 

Under the agreement, Sanofi will invest US$80 million in newly issued JHL shares at NT$90 per share. In addition, Sanofi will make an upfront payment of US$21 million to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL will lead the development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China. JHL is entitled to receive milestones of up to US$236 million and sales royalties.

The collaboration brings together complementary capabilities of the two companies and represents a commitment to expanding patient access to affordable high quality modern therapies through local development of biologics in China.

"Today is a turning point in JHL’s history," said Racho Jordanov, Co-Founder and CEO of JHL Biotech, "JHL was built on the foundation of world-class biologics capabilities. In our alliance with Sanofi, we are combining JHL’s development and manufacturing expertise with Sanofi’s strengths in commercialization. Together, we will make high-quality medicines affordable to more patients in China."

"The alliance reflects Sanofi’s long-term commitment to invest in China and to provide access to high quality therapeutics to Chinese patients," said Dr.Jean-Luc Lowinski, President of Sanofi China and SVP of Sanofi Asia, "JHL has quickly developed leading capabilities in the development of biologics and I am confident that our alliance will positively impact lives of patients in areas of high unmet medical needs in China." 

About Sanofi

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

For more information, please visit

About Sanofi China

In 1982, Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticals, vaccines, consumer healthcare and rare diseases (Genzyme) to animal health (Merial). Sanofi’s China headquarters in Shanghai are supported by 11 branches in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinan and Urumqi. As of 2015, Sanofi had more than 9,000 employees in China.

Sanofi has seven manufacturing facilities in China to meet the increasing demand of the China market. These plants are located in Beijing, Hangzhou (two plants), Tangshan, Shenzhen, Nanchang and Nanjing.

With Shanghai as headquarter of Sanofi China R&D and Asia Pacific R&D Hub, Sanofi’s capabilities span the entire R&D value chain from drug target identification to late-stage clinical studies. Sanofi focuses on China and Asia Pacific’s unmet medical needs, such as liver diseases, diabetes, oncology and cardiovascular diseases. 

For more information, please visit

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase development. JHL’s facility in Wuhan, China executes commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract work on behalf of select clients. For more information, please visit

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Innovent Biologics, Inc. Raises USD $260M in Series D Financing

– Capital Will Accelerate Expansion of Company’s Pipeline and Manufacturing Capacity of Innovative Therapeutic Biologics –

SHANGHAI, Nov. 29, 2016 /PRNewswire/ — Innovent Biologics, Inc., a leading biopharmaceutical company in China dedicated to the discovery, development manufacturing, and commercialization of high-quality biologics, announced today that it has raised $260 million in its Series D financing.

Future Industry Investment Fund (FIIF), a private equity fund managed by SDIC Fund Management Corporation Limited (SDIC Fund Management), a subsidiary of State Development & Investment Corporation, led the financing, along with other blue chip investors including China Life Private Equity Limited, Milestone, Ping An and Taikang Insurance Group. Innovent’s existing international investors, specifically Legend Capital, Temasek and Hillhouse Capital, also participated in this financing.

The funding will accelerate Innovent’s continued development of its robust pipeline of biologic therapeutics, several of which have entered clinical evaluation. Since its founding in August 2011, Innovent has built a robust portfolio of 12 product candidates for cancer, autoimmune disorders, ophthalmology and cardiovascular diseases. Innovent has filed eight IND applications and has four products in clinical development, three of which are currently in phase 3 clinical trials. Innovent’s achievements with its pipeline demonstrate the execution of the company’s strategy to rapidly bring innovative biologics to patients in China, a market still underserved by the therapeutic advances attained by biologic drugs worldwide.

Michael Yu, Ph.D., Innovent Biologics co-founder, Chairman and CEO, stated, "With the support from our investors and the Chinese government, Innovent has made significant progress in developing our portfolio of high-quality innovative products, building cGMP global-standard manufacturing and establishing global partnerships. We are gratified that our achievements have been recognized by a group of leading investors including SDIC Fund Management, China Life, Milestone, Ping An, Taikang Insurance Group and others. This financing will enable Innovent to better leverage the emerging opportunity in China to quickly develop affordable and high-quality biologic products to treat Chinese patients."

Simon Dazhong Lu, Managing Director of SDIC Fund Management, commented, "The Chinese biotechnology industry is in a golden period of rapid development, and Innovent is leading the way as the premier Chinese biologics company. We have conducted comprehensive due diligence on Innovent’s pipeline, drug development capability, product quality and manufacturing facilities, and believe that Innovent has huge potential and is expected to become a top-tier global biopharmaceutical company. We are pleased to invest and work with this elite team."

This Series D financing exceeded China’s previous record for reported biopharmaceutical industry investment and is one of the largest biopharmaceutical industry fundraising events in the world for both private and public financing markets in 2016. The financing will primarily support the accelerated development of innovative biopharmaceutical products, the expansion of manufacturing capacity and continued operations under rigorous cGMP requirements. Through this Series D round, Innovent has gained significant financial support from respected domestic and international investors as it advances the development of China’s biopharmaceutical industry as a whole.

About Innovent Biologics, Inc.

Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as SDIC Fund Management, China Life, Ping An, Taikang Insurance Group, Legend Capital, Temasek, Fidelity, Lilly Asia Ventures and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance.

About SDIC Fund Management Corporation Limited

Established in July 2009, SDIC Fund Management Corporation Limited is an independent, professional private equity company. It currently manages and advises more than RMB 50 billion of capital for a wide range of institutional investors including financial institutions, social security funds, and state-owned and private capital. SDIC Fund Management Corporation Limited is one of the largest professional private equity fund managers in China.

For more information, please visit


For partnering inquiries:
Blake Salisbury, VP of Business Development
[email protected];

For financing inquiries:
Jinbo Wang, VP of Finance
[email protected];

Investor and Media Contacts:
Tiberend Strategic Advisors, Inc.
Investors – Joshua Drumm, Ph.D.
[email protected]

Media – Andrew Mielach
[email protected]

U.S. News & World Report Releases 2017 Best Colleges Rankings

Princeton, Williams and UC–Berkeley take No. 1 Spots

WASHINGTON, Sept. 13, 2016 /PRNewswire/ — U.S. News & World Report today announced the 2017 Best Colleges rankings to help students worldwide compare the academic quality of more than 1,800 U.S.-based schools. Princeton University remains No. 1 in the Best National Universities category. For the 14th consecutive year, Williams College takes the top spot on the Best National Liberal Arts Colleges list.

California schools and military academies make a strong showing on the Top Public Schools lists. University of California—Berkeley is the No. 1 Top Public School among National Universities for the 19th year; the United States Naval Academy is the No. 1 Top Public School among National Liberal Arts Colleges.

The U.S. News rankings focus on academic excellence, with schools ranked on up to 15 measures of academic quality. Overall, the rankings emphasize student outcomes – including graduation and retention rates – which carry the most weight at 30 percent. The top National Universities and National Liberal Arts Colleges had significantly higher graduation and freshman retention rates than other schools:  

  • The average six-year graduation rate is 95 percent for the top 10 National Universities and 93.9 percent for the top 10 National Liberal Arts Colleges.
  • The average freshman retention rate is 98.1 percent for the top 10 National Universities and 96.6 percent for the top 10 National Liberal Arts Colleges.
  • For comparison, the average six-year graduation rate among all numerically ranked schools on the National Universities list is 71.3 percent, and the average freshman retention rate is 86.9 percent.
  • For comparison, the average six-year graduation rate among all numerically ranked schools on the National Liberal Arts Colleges list is 75.2 percent, and the average freshman retention rate is 85.6 percent.

"I encourage parents and students to use the wealth of data and information in Best Colleges to identify schools that suit their specific needs," said Brian Kelly, editor and chief content officer of U.S. News. "In addition to considering factors like location and cost, families should pay close attention to graduation and retention rates. These are important indicators of how well a school supports its students both academically and financially. Getting into a good school means nothing if you cannot graduate."

For students with specific career paths in mind, U.S. News ranks the top schools in undergraduate engineering and business. The rankings also encompass the Most Innovative Schools and a list of the A-plus Schools for B Students. School profiles include specifics on academic life, financial aid, student body makeup and more.

To help international students who are interested in studying abroad, the 2017 edition of Best Colleges includes a list of colleges and universities with the Most International Students. In addition, U.S. News publishes a resource center in Chinese to prepare Chinese students applying to U.S. universities. The special editorial section includes information on the admissions process, working with agents, paying for college and more.

The college ranking categories are based on the Carnegie Classification of Institutions of Higher Education, the most widely accepted classification system in U.S. higher education. In February 2016, Carnegie released official updates – called the "2015 update" – including to the Basic Classification used in the 2017 Best Colleges. As a result, about 12 percent of ranked schools moved into different categories compared with last year. The Carnegie classification system has been used by U.S. News since the first Best Colleges rankings in 1983.

In an exclusive arrangement, the launch of the 2017 Best Colleges is being sponsored by Fidelity Investments. To learn more about the U.S. News College Compass, which provides access to the complete rankings and data, or to order a copy of the "Best Colleges 2017″ guidebook (ISBN 978-1-931469-78-4), visit the online U.S. News store.

2017 U.S. News Best Colleges Rankings

National Universities       

National Liberal Arts Colleges

1. Princeton University (NJ)                 

1. Williams College (MA)

2. Harvard University (MA)          

2. Amherst College (MA)

3. University of Chicago (IL) (tie)       

3. Wellesley College (MA)

3. Yale University (CT) (tie)               

4. Middlebury College (VT) (tie)

5. Columbia University (NY) (tie)          

4. Swarthmore College (PA) (tie)

5. Stanford University (CA) (tie)   

6. Bowdoin College (ME)

7. Massachusetts Institute of Technology              

7. Carleton College (MN) (tie)

8. Duke University (NC) (tie)         

7. Pomona College (CA) (tie)

8. University of Pennsylvania (tie)   

9. Claremont McKenna College (CA) (tie)

10. Johns Hopkins University (MD)         

9. Davidson College (NC) (tie)

Top Public National Universities

National Universities                  

1. University of California–Berkeley       

2. University of California–Los Angeles (tie)  

2. University of Virginia (tie)         

4. University of Michigan–Ann Arbor                          

5. University of North Carolina–Chapel Hill        

Schools With Most International Students

National Universities                          

National Liberal Arts Colleges

Florida Institute of Technology: 33%             

Soka University of America (CA): 39.5%

New School (NY): 32.4%         

Pine Manor College (MA): 35%

Illinois Institute of Technology: 26.5%     

Mount Holyoke College (MA): 26.3%

University of Tulsa (OK): 25.8%      

Wesleyan College (GA): 23.9%

Suffolk University (MA): 23.2%          

Bryan Mawr College (PA): 23.4%

For more information, visit Best Colleges and continue the conversation on Weibo.

About U.S. News & World Report
U.S. News & World Report is a digital news and information company that empowers people to make better, more informed decisions about important issues affecting their lives. Focusing on Education, Health, Personal Finance, Travel, Cars and News & Opinion, provides consumer advice, rankings, news and analysis to serve people making complex decisions throughout all stages of life. More than 37 million people visit each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.